CNSP

Cns Pharmaceuticals Inc

5.80

Aug 25 • 3:59 PM ET -0.14 (-2.36%)

5.90

Aftermarket • 5:00 PM ET +0.10 (1.72%)

Healthcare Biotechnology USA Nano NASD

Peers: APRE BCDA BIVI GOVX KAPA KPRX LNAI CALC CVM NEUP

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	8.48M
Enterprise Value	-11.50M
Income	-16.70M
Sales	0.00M
Book/sh	12.45
Cash/sh	13.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Nov 08, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.47
P/C	0.42
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.85
Current Ratio	5.85
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-23.59
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	95.26% 85.25%
Sales past 3/5Y	- -
EPS Y/Y TTM	88.43%
Sales Y/Y TTM	-
EPS Q/Q	94.10%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-58.33% -

Insider Own	0.95%
Insider Trans	190.24%
Inst Own	19.19%
Inst Trans	3.30%
ROA	-91.64%
ROE	-106.62%
ROIC	-91.75%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.64%
SMA50	13.37%
SMA200	19.09%
Trades

Shs Outstand	1.46M
Shs Float	1.45M
Short Float	0.87%
Short Ratio	0.44
Short Interest	0.01M
52W High	10.59 -45.22%
52W Low	1.90 205.26%
Volatility	9.07% 6.94%
ATR (14)	0.44
RSI (14)	56.06
Beta	0.99
Rel Volume	0.30
Avg Volume	28.60K
Volume	8,561

Perf Week	-1.05%
Perf Month	14.40%
Perf Quarter	11.11%
Perf Half Y	95.29%
Perf YTD	10.48%
Perf Year	-11.31%
Perf 3Y	-99.99%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	1.00
Target Price	10.00
Prev Close	5.94
Price	5.80
Change %	-2.36%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-24-20	Initiated	Ladenburg Thalmann	Buy	$11

Aug-12-26 08:00AM	CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation (ACCESSWIRE) -8.91%
Jun-08-26 09:15AM	CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment (ACCESSWIRE)
May-14-26 08:00AM	CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress (ACCESSWIRE) -9.24%
May-04-26 10:30AM	BC-Most Active Stocks (Associated Press) +239.23%
07:00AM	CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing (ACCESSWIRE)
08:35AM	Loading…
Mar-11-26 08:35AM	CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline (ACCESSWIRE) -11.64%
Mar-02-26 08:25AM	CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team (ACCESSWIRE)
Feb-17-26 08:25AM	CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation (ACCESSWIRE) -5.78%
Jan-27-26 09:00AM	CNS Pharmaceuticals Issues Letter to Shareholders (ACCESSWIRE)
Dec-17-25 07:00AM	CNS Pharmaceuticals Announces CEO Transition (ACCESSWIRE) -6.40%
Nov-17-25 08:35AM	CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-10-25 08:45AM	CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting (ACCESSWIRE)
Sep-13-25 09:05AM	CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap (TipRanks)
Sep-03-25 09:15AM	CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference (ACCESSWIRE)
Aug-15-25 08:05AM	CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE) -15.59%
09:15AM	Loading…
Aug-14-25 09:15AM	CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (ACCESSWIRE) -11.19%
Jul-22-25 08:45AM	CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (ACCESSWIRE)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-18-25 08:00AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE) -10.71%
Jul-09-25 09:32AM	CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment (ACCESSWIRE)
Jun-24-25 09:15AM	CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287 (ACCESSWIRE)
Jun-05-25 08:05AM	CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit (ACCESSWIRE)
May-16-25 08:05AM	CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-13-25 09:35AM	CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +12.40%
07:00AM	CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 (ACCESSWIRE)
Apr-02-25 08:46AM	CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year (TipRanks)
Mar-25-25 08:00AM	CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme (ACCESSWIRE) -51.78%
Feb-26-25 09:05AM	CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing (ACCESSWIRE)
Feb-20-25 09:00AM	CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum (ACCESSWIRE) -10.50%
Feb-19-25 09:00AM	CNS Pharmaceuticals, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (ACCESSWIRE) -41.19%
08:30AM	Loading…
08:30AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE)
Feb-18-25 09:00AM	CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit (ACCESSWIRE)
Feb-10-25 08:00AM	CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference (ACCESSWIRE) +10.46%
Dec-05-24 09:10AM	CNS Pharmaceuticals to Host Virtual Analyst and Investor Day on December 11, 2024 (ACCESSWIRE)
09:10AM	CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 (ACCESS Newswire)
Nov-25-24 09:00AM	CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy (ACCESSWIRE) -7.56%
Nov-18-24 08:55AM	CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) (ACCESSWIRE) +14.18%
Nov-15-24 09:10AM	CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results (ACCESSWIRE) -11.61%
Nov-04-24 09:15AM	CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment (ACCESSWIRE)
Nov-01-24 09:00AM	CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (ACCESSWIRE)
Oct-23-24 02:50PM	CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -10.02%
Oct-10-24 09:00AM	CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment (ACCESSWIRE)
Oct-08-24 09:15AM	CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC (ACCESSWIRE) +11.37%
Sep-23-24 09:00AM	CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum (ACCESSWIRE)
Sep-12-24 09:00AM	CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement (ACCESSWIRE) -5.58%
Sep-04-24 09:05AM	CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (ACCESSWIRE)
Sep-03-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc. (GlobeNewswire)
Aug-27-24 09:10AM	CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (ACCESSWIRE) -7.11%
Aug-22-24 09:15AM	CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment (ACCESSWIRE)
Aug-15-24 08:00AM	CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results (ACCESSWIRE)
Jul-30-24 07:00AM	CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies (ACCESSWIRE) -60.58%
Jul-25-24 09:05AM	CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference (ACCESSWIRE)
Jul-16-24 09:15AM	CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series (ACCESSWIRE) -5.93%
Jul-11-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +20.00%
Jul-03-24 11:10AM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) +15.87%
Jun-26-24 08:00AM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -35.21%
Jun-14-24 03:11PM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -22.93%
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE) -27.72%
Jun-03-24 08:05AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE) -39.87%
May-20-24 08:30AM	CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase (ACCESSWIRE)
May-16-24 11:53AM	CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace) +12.68%
07:45AM	CNS Pharmaceuticals Reports First Quarter 2024 Financial Results (ACCESSWIRE)
Apr-23-24 09:00AM	CNS Pharmaceuticals to Present at the LSX World Congress 2024 (ACCESSWIRE) +5.47%
Apr-22-24 10:15AM	CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity (ACCESSWIRE)
Apr-01-24 11:52PM	CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace) -14.54%
05:00PM	CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements (ACCESSWIRE)
09:05AM	CNS Pharmaceuticals to Present at Two Investor Conferences in April (ACCESSWIRE)
Jan-29-24 09:00PM	CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering (ACCESSWIRE) -20.94% -27.67%
Jan-18-24 08:45AM	Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors (ACCESSWIRE)
Jan-17-24 08:45AM	CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Dec-18-23 08:35AM	CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin (ACCESSWIRE) -23.12%
Dec-06-23 09:00AM	How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure (ACCESSWIRE)
Nov-22-23 09:05AM	CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy (ACCESSWIRE) +7.66%
Nov-16-23 10:00AM	CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate (ACCESSWIRE) +9.38%
Nov-15-23 08:00AM	CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End (ACCESSWIRE) +14.97%
Oct-19-23 09:05AM	CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference (ACCESSWIRE) +11.24%
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE) +11.25%
Oct-16-23 09:00AM	Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals Innovative Approach To Treatment Could Offer Hope (ACCESSWIRE) +20.00%
Oct-11-23 08:45AM	CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date (ACCESSWIRE) +10.28%
Sep-07-23 08:45AM	CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Sep-05-23 08:45AM	CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE) -6.51%
Aug-14-23 08:35AM	CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy (ACCESSWIRE) -12.81%
07:35AM	CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones (ACCESSWIRE)
Aug-03-23 08:15AM	CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference (ACCESSWIRE)
08:00AM	CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Jul-27-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference (ACCESSWIRE)
Jul-05-23 08:45AM	CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series (ACCESSWIRE)
Jun-14-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE) +9.00%
May-25-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
May-15-23 08:35AM	CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-08-23 08:45AM	Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors (ACCESSWIRE) -5.99%
May-03-23 08:45AM	CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC (ACCESSWIRE) +26.32%
Apr-27-23 08:45AM	CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study (ACCESSWIRE)
Apr-17-23 06:54AM	Daily Vickers Top Buyers & Sellers for 04/17/2023 (Argus Research) +17.02%
Apr-10-23 08:45AM	Over 100 Patients Now Enrolled in CNS Pharmaceuticals (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Apr-06-23 09:05AM	CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (ACCESSWIRE) -13.38%
Apr-03-23 08:05AM	CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-29-23 09:05AM	CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event (PR Newswire)
Mar-13-23 07:05AM	CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues (PR Newswire) +6.40%
Mar-09-23 09:05AM	CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland (PR Newswire) -8.16%

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

PresidentMr. Rami Levin M.B.A.

Chief Financial OfficerMr. Steve O'Loughlin M.B.A.

M.Sc.Mr. Eric Faulkner M.B.A.

Chief Business OfficerMr. Dylan Wenke M.B.A.

M.D.Dr. E. Lynne Kelley F.A.C.S.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fisher Michal	Director	May 18 '26	Buy	5.00	2,000	10,000	2,000	Aug 18 09:01 AM
Charles Faith L.	Director	May 18 '26	Buy	4.79	7,100	34,002	7,100	May 20 09:03 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNSP

Cns Pharmaceuticals Inc

Upgrade your Finviz experience